Low-vision rehab could improve quality of life

Article

Low-vision rehabilitation can lead to significant improvements in overall quality of life, according to study published in the April issue of Investigative Ophthalmology and Visual Science.

Low-vision rehabilitation can lead to significant improvements in overall quality of life, according to study published in the April issue of Investigative Ophthalmology and Visual Science.

Ecosse L. Lamoureux, from the University of Melbourne, Australia and colleagues conducted a study to evaluate the effectiveness of a multidisciplinary low-vision rehabilitation programme on quality of life, measured using the Impact of Vision Impairment (IVI) instrument.

A total of 124 female and 68 male (mean age, 80.3 years) first-time referrals to low-vision clinics were assessed before and after rehabilitation. Rasch analysis was used to estimate the three IVI subscales and overall values on an interval scale. Analysis of Variance between groups (ANOVA) was used to determine whether presenting visual acuity (VA) had an interaction effect with rehabilitation change. Cohen d values were used to estimate the magnitude of change and the standardized response mean (SRM) procedure was used to determine the clinical significance of such changes.

Most subjects (62%) had age-related macular degeneration (AMD) and were categorized as moderately to severely vision impaired (<6/18; 78%). Following rehabilitation, significant improvements were recorded for the overall IVI score (p=0.006) and two subscales: 'reading and accessing information' and 'emotional well-being' (p=0.007 and 0.009, respectively). However, no significant improvement was recorded for the 'mobility and independence' subscale (p=0.07). The level of post-rehabilitation improvement was found to be relatively moderate (Cohen d=0.17-0.30) and clinically modest (SRM=0.22-0.42).

The authors concluded that significant improvements in quality of life can be achieved through low-vision rehabilitation, however, the magnitude and clinical significance of rehabilitation-induced gains are modest. They suggest that further investigation in other models of rehabilitation are required to optimize the quality of life gains that could be achieved.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.